Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's Co-founder and Chief Scientific Officer, Michael Klichinsky, PharmD, PhD, will be presenting at the conference on Tuesday, February 25 at 10:30 am ET.
Interested parties can access an audio webcast of the presentation through the Company's Investor Events section on their Investor Relations webpage. The recording will remain available for a time after the event.
Carisma Therapeutics (Nasdaq: CARM), pioniera nelle terapie focalizzate sui macrofagi, ha annunciato la sua partecipazione al prossimo 3° Conferenza Virtuale Annuale sulla Terapia Cellulare H.C. Wainwright. Il cofondatore e Chief Scientific Officer dell'azienda, Michael Klichinsky, PharmD, PhD, presenterà alla conferenza il martedì 25 febbraio alle 10:30 ET.
Le parti interessate possono accedere a un webcast audio della presentazione attraverso la sezione Eventi per Investitori della pagina delle Relazioni con gli Investitori dell'azienda. La registrazione rimarrà disponibile per un certo periodo dopo l'evento.
Carisma Therapeutics (Nasdaq: CARM), pionera en terapias centradas en macrófagos, ha anunciado su participación en la próxima 3ª Conferencia Virtual Anual sobre Terapia Celular H.C. Wainwright. El cofundador y Director Científico de la compañía, Michael Klichinsky, PharmD, PhD, presentará en la conferencia el martes 25 de febrero a las 10:30 am ET.
Las partes interesadas pueden acceder a una transmisión de audio de la presentación a través de la sección de Eventos para Inversores en la página de Relaciones con Inversores de la empresa. La grabación estará disponible durante un tiempo después del evento.
Carisma Therapeutics (Nasdaq: CARM)는 대식세포 중심의 치료법에서 선두주자로서 H.C. Wainwright 제3회 연례 세포 치료 가상 회의에 참여한다고 발표했습니다. 회사의 공동 창립자이자 최고 과학 책임자인 Michael Klichinsky, PharmD, PhD가 2월 25일 화요일 오전 10시 30분 ET에 회의에서 발표할 예정입니다.
관심 있는 분들은 회사의 투자자 관계 웹페이지 내 투자자 이벤트 섹션을 통해 발표의 오디오 웹캐스트에 접속할 수 있습니다. 녹화는 이벤트 이후 일정 시간 동안 이용 가능합니다.
Carisma Therapeutics (Nasdaq: CARM), pionnier dans les thérapies axées sur les macrophages, a annoncé sa participation à la prochaine 3ème Conférence Virtuelle Annuelle sur la Thérapie Cellulaire H.C. Wainwright. Le co-fondateur et directeur scientifique de l'entreprise, Michael Klichinsky, PharmD, PhD, présentera lors de la conférence le mardi 25 février à 10h30 ET.
Les parties intéressées peuvent accéder à un webinaire audio de la présentation via la section Événements pour Investisseurs sur la page des Relations avec les Investisseurs de l'entreprise. L'enregistrement restera disponible pendant un certain temps après l'événement.
Carisma Therapeutics (Nasdaq: CARM), ein Pionier in der Makrophagen-fokussierten Therapie, hat seine Teilnahme an der bevorstehenden 3. Virtuellen Jahrestagung zur Zelltherapie H.C. Wainwright angekündigt. Der Mitbegründer und Chief Scientific Officer des Unternehmens, Michael Klichinsky, PharmD, PhD, wird am Dienstag, den 25. Februar um 10:30 Uhr ET auf der Konferenz präsentieren.
Interessierte können über den Bereich Investorenveranstaltungen auf der Investor-Relations-Webseite des Unternehmens auf einen Audio-Webcast der Präsentation zugreifen. Die Aufnahme wird nach der Veranstaltung für eine gewisse Zeit verfügbar sein.
- None.
- None.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.
Investors:
Shveta Dighe
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-hc-wainwright-3rd-annual-cell-therapy-virtual-conference-302379463.html
SOURCE Carisma Therapeutics Inc.
FAQ
When is Carisma Therapeutics (CARM) presenting at the H.C. Wainwright Cell Therapy Conference?
How can investors access CARM's presentation at the H.C. Wainwright Conference?
Who will represent CARM at the H.C. Wainwright Cell Therapy Conference?
Will CARM's H.C. Wainwright Conference presentation be available for replay?
